World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF SQUAMOUS CELL CARCINOMA USING SIMILAR MOLECULE - LAMBROLIZUMAB

Arshiya Tarannum*, Dr. Syed Ahmed Hussain, Umaima Batool Osmani, Raheem Unnisa Shaik, Maimuna Fatima, Faheem Unnisa and Nazneen

ABSTRACT

Aim: To evaluate the cytotoxic effects of Lambrolizumab, a PD-1 immune checkpoint inhibitor, on kidney cancer cell lines and compare its efficacy with Cisplatin using various in vitro assays. Objective: To assess Lambrolizumab's potential as a therapeutic alternative or adjunct to Cisplatin for the treatment of Squamous Cell Carcinoma (SCC). Research: Kidney cancer cell lines were treated with different concentrations of Lambrolizumab and Cisplatin. Five cell viability assays were performed, namely MTT, CellTiter-Glo, Alamar Blue, Sulforhodamine B (SRB), and LDH cytotoxicity assays. The results showed a dose-dependent decrease in cell viability with Lambrolizumab, similar to the effects observed with Cisplatin. The LDH cytotoxicity assay indicated substantial cell membrane damage at higher Lambrolizumab concentrations, suggesting its potential as a cytotoxic agent. Conclusion: Lambrolizumab demonstrated strong cytotoxic effects across multiple assay methods and showed comparable efficacy to Cisplatin at higher concentrations. These findings suggest that Lambrolizumab could serve as a viable alternative or complement to traditional chemotherapy for SCC treatment, warranting further clinical investigations.

[Full Text Article]   [Download Certificate]